Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 26, 2022 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting

Data demonstrated robust anti-tumor activity of BMF-219 and mechanistic evidence for novel inhibition of menin protein in preclinical models of Diffuse Large B-cell Lymphoma (DLBCL) and multiple...
August 01, 2022 16:05 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights

Continued to make significant progress advancing BMF-219, the company’s lead investigational orally administered covalent menin inhibitor, in multiple oncology indications COVALENT-101 (Phase I) study...
July 01, 2022 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes

Biomea to present two oral abstracts across multiple animal models highlighting the ability of BMF-219, a covalent menin inhibitor, to significantly lower HbA1C (approximately two-fold greater...
June 22, 2022 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial

BMF-219, a covalent menin inhibitor, is the first menin inhibitor administered to patients with relapsed/refractory (R/R) multiple myeloma (MM)Patients with R/R MM and R/R diffuse large B-cell...
June 04, 2022 11:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

Menin acts as a ‘brake’ on beta cell regeneration; inhibiting menin function with BMF-219 may increase beta cell production and function, thereby increasing insulin levels and controlling high glucose...
June 02, 2022 18:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Participate in Jefferies Healthcare Conference

REDWOOD CITY, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small...
June 01, 2022 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models at ADA 2022

Company to host virtual investor R&D event on Monday, June 6, 2022 at 4:05 PM EDT featuring covalent menin inhibitor, BMF-219, as a potential novel treatment for type 2 diabetes REDWOOD CITY,...
May 26, 2022 18:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Present New Preclinical Data Showing BMF-219’s Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022

BMF-219 is the first investigational menin inhibitor in clinical development to show potential as a therapeutic agent for CLLBMF-219, a covalent menin inhibitor, demonstrated potency across ex...
May 20, 2022 13:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Attend H.C. Wainwright Global Investment Conference

REDWOOD CITY, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small...
May 19, 2022 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3

BMF-500, an investigational third-generation covalent inhibitor of FLT3, demonstrated picomolar IC50 values across key FLT3 isoforms, potentially making it the most potent inhibitor of its classHighly...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right